The market for oral solid doses (OSD) manufacturing is now expanding at a rapid pace. It is expected to have a phenomenal increase in value, reaching a stunning US$926 billion by 2027, with a CAGR of 6.5%.
The oral solid dosage manufacturing market is concerned with manufacturing and packaging medicines in solid form, such as tablets, capsules, and powders. These dosage forms are frequently utilized because of their comfort, simplicity of administration, and stability. The market for oral solid dosage production has grown significantly in recent years due to rising demand for generic pharmaceuticals, an older population, and advances in pharmaceutical formulations. This report discusses the major drivers, opportunities, and challenges in the oral solid dosage manufacturing market while exploring regional growth and recent developments of key players.
Key Report Finding
Increasing Demand for Generic Drugs
The increased desire for low-cost healthcare solutions has resulted in a major growth in the use of generic medications. Because of their simplicity of manufacture, stability, and patient compliance, oral solid dosage forms, such as tablets and capsules, are the most favored formats for generic pharmaceuticals. The availability of a diverse variety of generic pharmaceuticals in oral solid dosage forms propels the industry forward.
Growing Aging Population
The world population is quickly aging, increasing the prevalence of chronic illnesses, including cardiovascular disease, diabetes, and respiratory ailments. Long-term treatment required for the older population is simple and efficient via oral solid dose forms of drug delivery. The aging population is a major driver of the oral solid dosage manufacturing industry.
Advancements in Pharmaceutical Formulations
The pharmaceutical industry is always working to create new medication formulations that increase patient compliance and therapeutic results. Modified-release formulations, combination medications, and tailored medicines in oral solid dose forms have all been made possible by technological advances. These developments have increased the market prospects for manufacturing oral solid dosages.
Demand for oral solid dosage forms is rapidly increasing in expanding regions like China, India, Brazil, and Southeast Asia. These areas are seeing rapid economic expansion, rising healthcare costs, and a growing middle-class population. Rising demand for affordable healthcare and the growth of pharmaceutical production capabilities provide profitable prospects for market participants in these regions.
Contract Manufacturing Organizations (CMOs)
In the pharmaceutical sector, outsourcing oral solid dosage manufacture to contract manufacturing organizations (CMOs) is gaining popularity. CMOs provide cost-effective and flexible production options, allowing pharmaceutical businesses to concentrate on R&D. The expanding trend of outsourcing manufacturing operations allows CMOs to extend their services and meet the growing demand for oral solid dosage forms.
Manufacturing advancements such as continuous production and 3D printing transform oral solid dose manufacturing. Continuous manufacturing enables real-time process control, shorter manufacturing times, and higher product quality. 3D printing allows for tailored drugs with exact doses and customizable forms. These technical advancements allow businesses to improve their production skills and offer unique goods.
Stringent Regulatory Requirements
The oral solid dosage manufacturing market must follow FDA regulations in the US and the European Medicines Agency (EMA) in Europe. Manufacturers face major hurdles in adhering to Good Manufacturing Practices (GMP) and assuring product quality and safety. Noncompliance can result in product recalls, regulatory penalties, and brand reputation harm.
The oral solid dosage production market is extremely competitive, with multiple firms fighting for market share. The fierce rivalry is fueled by established pharmaceutical corporations, generic medicine producers, contract manufacturing organizations, and rising entrants. Price pressures, patent expirations, and the requirement for product uniqueness make it difficult for businesses to sustain profitability and market position.
Supply Chain Management
Effective supply chain management is critical for oral solid dosage producers. Significant issues include the timely purchase of raw materials, assuring their quality and availability, managing inventory levels, and optimizing distribution networks. Any interruption in the supply chain can cause production delays, cost increases, and customer dissatisfaction.
The oral solid dosage manufacturing market is divided geographically into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Because of well-established pharmaceutical businesses, technological improvements, and high healthcare spending, North America maintains a substantial proportion of the oral solid dosage manufacturing market. The area has a solid regulatory structure with a significant emphasis on quality compliance. Europe is another important oral solid dosage production market, owing to rising generic medicine demand and a large senior population. The region features an advanced healthcare infrastructure as well as strict regulatory norms.
The oral solid dosage manufacturing industry in the Asia Pacific is rapidly expanding. Market expansion is aided by an increasing population, rising disposable income, and increased healthcare expenditure in nations such as China and India. Several pharmaceutical businesses use the region as a production base. Because of the rising frequency of chronic illnesses and expanding healthcare infrastructure, Latin America, the Middle East, and Africa also provide considerable growth potential for oral solid dosage manufacture. Government attempts to offer inexpensive healthcare are driving market expansion.
Middle East and Africa:
Company Recent Development
Major players operating in the Oral Solid Dosage Manufacturing market are:
Piramal Pharma Solutions: Piramal Pharma Solutions (PPS) has announced the acquisition of G&W Laboratories Inc.'s solid oral dosage medicinal product factory in Sellersville, Pennsylvania. This purchase broadens PPS's North American capabilities, enabling them to provide product and process research, production, and packaging of solid oral dosage forms, liquids, creams, and ointments. It also boosts PPS's integrated services offering and gives them robust oral dosage capabilities across three continents while improving their capacity to manage powerful formulations in North America.
Pfizer Inc.: Pfizer Inc. announced a $120 million investment in its Kalamazoo, Michigan, plant to produce the oral Covid-19 medication PAXLOVIDTM. Pfizer intends to increase its OSD production capacity to fulfill the rising demand for solid dosage forms and strengthen its position in the OSD manufacturing market.
The oral solid dosage manufacturing market is expanding rapidly, owing to rising generic medication demand, an aging population, and advances in pharmaceutical formulations. While considerable prospects exist in growing countries, contract manufacturing, and technological breakthroughs, the industry faces regulatory compliance, strong competition, and supply chain management issues. Companies in the market are focused on strategic innovations, technical improvements, and collaborations to strengthen their market position and match the healthcare industry's shifting demands.
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.View Methodology